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Abstract
A Leishmania model to explain microbial virulence in chronic infectious diseases is proposed. All
these diseases progress from infection to symptomatic phase to host death or recovery. The
outcome of each phase is depicted to result from the interactions of a distinct group of parasite
molecules with a specific host immune compartment. The first group consists of invasive/evasive
determinants, which are largely parasite cell surface and secreted molecules. Their activities help
parasites establish infection by overcoming host immunologic and non-immunologic barriers. These
determinants do not cause disease per se, but are indispensable for infection necessary for the
development of a disease-state. The second group of parasite molecules consists of
"pathoantigenic" determinants – unique parasite epitopes present often within otherwise highly
conserved cytoplasmic molecules. Immune response against these determinants is thought to result
in immunopathology manifested as clinical signs or symptoms, namely the virulent phenotype. The
third group of parasite molecules is hypothetically perceived as vaccine determinants. Their
interactions with the host immune system lead to the elimination or reduction of parasites to effect
a clinical cure. Differential expression of these determinants alone by parasites may alter their
interactions with the hosts. Virulent phenotype is consequently presented as a spectrum of
manifestations from asymptomatic infection to fatality. A secondary level of regulation lies in host
genetic and environmental factors. The model suggests that different parasite determinants may be
targeted by different strategies to achieve more effective control of leishmaniasis and other similar
diseases.
Introduction
Some Leishmania species are inherently endowed as path-
ogens, as they cause diseases collectively known as leish-
maniasis. The degree of their pathogenicity, traditionally
defined as "virulence", is manifested as a spectrum of clin-
ical symptoms in human diseases [1]. Those causing a
self-healing cutaneous leishmaniasis are considered as
less virulent than those causing the potentially fatal kala-
azar or visceral leishmaniasis. Disease entities with graded
clinical severity exist between these two extremes. Al-
though Leishmania virulence may be modulated by envi-
ronmental and genetic factors of their mammalian hosts
[2], and sand fly vectors [3], molecular determinants of
Leishmania spp. are the key elements. This is considered to
be the case, since there is no leishmaniasis without infec-
tion by intact living Leishmania. That is, leishmaniasis
does not occur, or at least has not been successfully dupli-
cated experimentally, by injection or manipulation of an-
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parasites. There is no evidence in the literature that Leish-
mania spp. produce "toxins" in the conventional sense to
directly cause the clinical symptoms of leishmaniasis.
How Leishmania cause leishmaniasis is thus a complicated
issue, involving apparently multiple factors of Leishmania
origin.
Work undertaken in the past two decades to elucidate
host-parasite cellular interactions has made this point ap-
parent. It is clear that Leishmania possess infection-related
molecules (=invasive/evasive determinants) [1], which al-
low them to establish successful intracellular parasitism in
phagolysosomes or parasitophorous vacuoles of macro-
phages [4]. In human leishmaniasis, these mononuclear
phagocytes are invariably seen as the only parasitized
cells. They are thus undoubtedly the principal host cells of
Leishmania, although experimental evidence exists for
leishmanial infection of other cell types, e.g. dendritic
cells [5] and fibroblasts [6,7]. The association of Leishma-
nia with macrophages at the cellular level is characterized
as akin to "symbiosis" [8]. This notion was proposed from
observations of host-parasite cellular interactions in the L.
amazonensis-J774 macrophage in vitro system [9]. In that
case, the infection produces no acute cytopathology or
rapid cytolysis of the host cells. It is essentially a self-re-
newable or self-sustainable host-parasite in vitro system.
Since human disease does occur with infection of macro-
phages in vivo, it is likely that the pathology and clinical
symptoms may originate from interactions of these infect-
ed macrophages with other elements in the host. We pro-
pose here that some parasite-specific antigens, derived
from the infected cells, interact with the host immune sys-
tem in a negative way, directly responsible for the immu-
nopathology manifested as the clinical symptoms seen in
leishmaniasis. Consistent with this notion are findings
that kala-azar patients produce large amounts of Leishma-
nia-specific, but non-protective antibodies against certain
intracellular antigens of these organisms [10].
A hypothetical model is thus proposed accordingly, de-
picting that Leishmania virulence results from interactions
of differentLeishmania determinants with separate com-
partments of host immune system, namely those for in-
fection and those involved in immunopathology. If the
hypothetical model proves correct, the two groups of de-
terminants may be targeted differently by molecular ge-
netic approaches relevant to the control of leishmaniasis.
Invasive/evasive determinants of Leishmania are crucial for 
infection, but produce no pathology in the host
These determinants include most, if not all Leishmania
molecules that have been studied as "virulence factors" in
the literature (see Fig. 1). All these molecules appear to
play certain roles in Leishmania infection of macrophages
[1]. They are referred to here as invasive/evasive determi-
nants because they help Leishmania successfully establish
intracellular parasitism in the following sequential events:
(A) evasion of humoral lytic factors; (B) attachment of
parasites to macrophages followed by their intracellular
entry into these phagocytes; (C) the intracellular survival
of the endocytized parasites; (D) promastigote-to-amas-
tigote differentiation; and (E) replication of the amastig-
otes. The categorization of the host-parasite cellular
interactions into sequential events pertains to the primary
infection of macrophages in the mammalian hosts by pro-
mastigotes. Events (A) – (C) and (E) are relevant as well to
the secondary infection of macrophages by amastigotes
from already infected cells. The spreading of amastigotes
to infect additional cells must be considered as crucial for
the development of leishmaniasis. However, it may be
mechanistically a rather simple event in considering nor-
mal functions of macrophages. One of their functions is
to scavenge damaged or dying cells and their cellular de-
bris, which may include degenerating cells (due to heavy
parasitization), parasitophorous vacuoles and even re-
leased amastigotes with adherent host molecules in leish-
maniasis.
Much attention has been thus devoted to the infection of
macrophages by promastigotes, although the manner, by
which their molecules (listed in Fig. 1) actually function
in infection remains to be elucidated. Data obtained from
different host-parasite systems are also not always consist-
ent even for the molecules more extensively studied, like
gp63 and LPG. Gp63 is an ecto-metalloprotease that is es-
pecially abundant in the surface of promastigotes and also
released by this stage of Leishmania[11]. Gp63 is known to
help promastigotes in event (A) by rendering them resist-
ant to complement-mediated cytolysis [12]. It also ap-
pears to act, (perhaps, together with LPG) in event (B),
namely infection of macrophages by promastigotes via re-
ceptor-mediated endocytosis [13–16]. Both may be im-
Figure 1
Some invasive/evasive determinants of Leishmania proposed
to play important roles in their infection of mammalian hosts.Page 2 of 7
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survival [16–18]. Some of the other molecules listed in
Fig. 1 may be involved directly or indirectly in these and/
or the remaining events. Parasite molecules involved in
events (D) and (E) for differentiation and replication of
intracellular Leishmania may have additional functions
beyond infection, especially in the latter case. Regardless
of the functional and definitional ambiguity associated
with these determinants, there is no evidence that they di-
rectly cause the clinical symptoms seen in leishmaniasis.
For example, repeated injections of susceptible animals
with gp63 or LPG do not reproduce the typical symptoms
of leishmaniasis, e.g. various types of cutaneous lesions or
hepatosplenomegaly and other clinical signs related to
kala-azar.
Leishmania pathoantigenic determinants elicit host immu-
nopathology as the principal cause of clinical symptoms
Fig. 2 lists a number of Leishmania antigens found to elicit
antibodies often at high titers in kala-azar patients [10].
The data presented were summarized from articles pub-
lished by others and some are proposed hypothetically.
These Leishmania antigens are identified by Western blot
analysis and/or by immunoscreening of Leishmania ex-
pression libraries with patients' sera.
Notably, Fig. 2 does not include the invasive/evasive de-
terminants discussed in the foregoing paragraph. This is
not to say that patients of leishmaniasis do not produce
any antibodies against these determinants. There have
been a number of publications, which demonstrated the
presence of, for example, anti-LPG and anti-gp63 antibod-
ies in these patients. However, the titers against these in-
vasive/evasive determinants are insignificant in
comparison to those listed in Fig. 2. Perhaps, this is not
unexpected for a successful parasite, like Leishmania. Since
the invasive/evasive determinants often exist on the cell
surface and/or are secreted, they bear the brunt of expo-
sure to and confrontation with the host immune system.
Evolutionary pressure may well select these invasive/eva-
sive determinants for low antigenicity, thereby escaping
from neutralization by specific antibodies and/or other
lytic factors to ensure successful parasitism.
Another striking feature of those listed in Fig. 2 is that they
are all conserved structural or soluble cytoplasmic pro-
teins, which are often complexed with other molecules to
form subcellular particles. Although some of them, e.g.
histones and heat shock proteins, are seemingly shared
with those found in autoimmune diseases, they are not
cross-reactive. Epitope-mapping reveals unique Leishma-
nia sequences, which are recognized only by sera from pa-
tients with kala-azar [10]. One example worthy of
mention is the unique 117 bp repeats in the Leishmania ki-
nesin-like gene [19]. It is expressed by the amastigotes of
visceralizing Leishmania, but not by cutaneous species.
Sera from human kala-azar patients contain antibodies
specific to the 39 amino acid peptides encoded by the 117
bp repeats (recombinant products =rK39). Anti-rK39 anti-
bodies reach exceedingly high titers as much as 10-6 in In-
dian kala-azar patients [20]. Although this antigen has
been used successfully for serodiagnosis of active kala-
azar cases, it is difficult to assign any protective function
for the specific antibodies at such high titers produced
against this and other similar antigens. The antigens of
concern are in the cytoplasm of intracellular amastigotes
and thus beyond the reach of these antibodies. Their po-
tential contributions to immunopathology are apparent,
e. g. albumin-IgG ratio reversal in the plasma and hyper-
plasia of plasma cells in the lymphoid organs in kala-azar.
Similarly, some Leishmania-specific T-cell epitopes may
also exist and cause additional immunopathology, al-
though these epitopes have not been extensively studied
in human leishmaniasis. Recent work in the direction of
elucidating protective immunity has identified T-cell
epitopes, which exist also in Leishmania cytoplasmic mol-
ecules [21].
A hypothetical model for Leishmania virulence involving 
sequential actions of invasive/evasive- and pathoantigenic 
determinants
Fig. 3 depicts schematically Leishmania invasive/evasive-
and pathoantigenic determinants as different groups of
parasite virulence-related molecules. Presumably, they in-
teract sequentially with different compartments of the
host immune system to cause leishmaniasis. The invasive/
evasive determinants of Leishmania help them overcome
the host immune and non-immune barriers to establish
intracellular infection of macrophages. This infection by
itself does not cause the disease, but it is a prerequisite for
Figure 2
Some Leishmania pathoantigenic determinants proposed to
cause immunopathology manifested as the clinical symptoms
in leishmaniasis. The molecules listed have been found to
contain immunogenic B-cell epitopes.Page 3 of 7
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transition from asymptomatic phase to symptomatic
phase, especially when host immunity becomes down-
regulated. The latter event alone produces no leishmania-
sis without persistence of the infection. The invasive/eva-
sive determinants are thus virulence factors in that sense,
even though they contribute only indirectly to the virulent
phenotype. During the subsequent chronic course of in-
fection, it appears that some intracellular amastigotes are
killed or lysed inadvertently due, perhaps, to the incom-
plete protection by their invasive/evasive determinants. As
a result of this, some cytoplasmic molecules of amastig-
otes are exposed to the host immune system. The resulting
immune response to these unique epitopes does not con-
tribute to the anti-Leishmania immunity, but to the clini-
cal symptoms observed in leishmaniasis. Thus,
Leishmania determinants of infection and immunopa-
thology are considered here as different, but sequentially
necessary components for the expression of virulence.
Regulation of Leishmania virulence
According to the hypothetical model, it is possible to en-
vision the regulation of Leishmania virulence via differen-
tial expression or qualitative differences of the invasive/
evasive and pathoantigenic determinants. Virulence is
manifested in a clinical setting as a spectrum of human
diseases with different severity, ranging from asympto-
matic infection to the appearance of self-healing nodules
to necrotic, diffuse mucocutaneous lesions to fatal viscer-
alizing disease. Up- or down-regulation of either group of
individual determinants quantitatively or qualitatively
alone can conceivably result in the spectrum of the clinical
outcomes seen. The extreme scenarios of asymptomatic
infection and fatal outcome thus may be due to a pattern
of varying expression of these determinants. In this view,
Leishmania determinants are considered as the driving
force of virulent phenotype. Host and vector determinants
are undoubtedly involved, but they play a secondary or
passive role in natural conditions.
Fig. 4 considers Leishmania virulence at the gene level
based on hypothetical grounds and on some gene knock-
out experimental data in the literature. There appear to be
three functional groups of genes involved: (A) Positive
contributors for the multiple determinants already dis-
cussed (Fig. 4., Blue, Green and Yellow squares with "+");
(B) negative contributors (pink square with "-") coding
for products, which reduce virulence; and (C) facultative
contributors (Red square blank), which normally do not
participate in virulence, but do so in the absence of a pos-
itive contributor. Normally, the virulent phenotype seen
in a given condition represents a balanced presence of
positive and negative genes with no involvement of the
facultative ones (Fig. 4, 1st row, double-headed horizon-
tal arrow). When one of the positive genes is silenced or
lost, virulence may decrease, as expected (Fig. 4, 2nd row,
downward arrow). Alternatively, it may remain un-
changed when the gene of concern is functionally "backed
Figure 3
A hypothetical model to explain virulent phenotype in leishmaniasis. The three groups of determinants are thought to interact
with host immune system independently, but may progress sequentially to produce the spectrum of subclinical and clinical
manifestions as the basis of virulent phenotypes seen.Page 4 of 7
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regulation of its expression (Fig. 4, 3rd Row, duplication
of the green squares with "++") or with that of a facultative
gene (Fig. 4, 4th row, red square with "+"). This scenario
may explain the experimental findings that knockouts of
"virulence genes" do not always result in changes in the
phenotype expected. Silencing or loss of the negative gene
is accompanied by an increase in virulence (Fig. 4, 6th
Row, upward arrow). There is at least one example in the
literature for the presence of negative genes [22].
The hypothesis proposed is speculative, especially for the
presence of the "back-up" genes. Although they have not
been demonstrated experimentally in Leishmania, func-
tionally overlapping genes with very different sequences
are expected to exist, in keeping with the proposed contri-
bution of such genes to genetic flexibility in biological sys-
tems [23]. If such a strategy should exist in Leishmania and
contribute to the regulation of their virulence, the evolu-
tionary pressure of maintaining successful parasitism
might favor this mechanisim for the invasive/evasive de-
terminants, but not for the pathoantigenic determinants.
Can we temper with Leishmania virulence genes to deal 
with leishmaniasis?
More genetic and functional data for the various determi-
nants discussed are needed to consider this question more
thoroughly. On hypothetical grounds, it is possible to
consider that: (A) the invasive/evasive determinants may
be targeted for developing specific inhibitors to prevent
infection; and (B) the pathoantigenic determinants may
be suitable targets for considering "molecular attenua-
tion" of virulence by gene deletions or modifications,
thereby producing infective, but non-pathogenic mutants
for vaccination. The schemes related to the second pro-
posal may be more interesting for further discussion.
It is feasible to begin the discussion with the self-curing
simple cutaneous leishmaniasis. In this case, "host protec-
tive determinants" of Leishmania origin are depicted to
emerge with the progression of the infection from "dis-
ease" to spontaneous "cure" (see Fig. 3). These hypotheti-
cal determinants may be the "natural vaccines", which
interact with the host immune system in a positive way to
cure the disease. Although they have not been identified
and isolated, there are ongoing research efforts toward
this end [21]. On the other hand, "Leishmanization" has
been practiced for centuries by inoculating or immunizing
individuals with live Leishmania. Although this process
Figure 4
Regulation of Leishmania virulence at genetic levels. Blue, Green and Yellow squares with "+", Positive contributors for the mul-
tiple determinants discussed; pink square with "-", negative contributors coding for products, which reduce virulence; Red
square blank, Facultative contributors, which do not contribute to virulence under the normal conditions.Page 5 of 7
(page number not for citation purposes)
Kinetoplastid Biology and Disease 2002, 1 http://www.kinetoplastids.com/content/1/1/1leads to development of cutaneous lesions, it provides
life-long protection to re-infection by the same species af-
ter cure. It is theoretically possible to improve "Leishman-
ization" by several potential schemes. One is to
genetically engineer parasites with "suicidal cassettes"
[24] for self-destruction as a strategy for vaccination, as
has been already carried out in experimental animals [25].
It would be of further interest to improve this by "immu-
nizing" susceptible hosts with such transgenic Leishmania,
which are responsive to external signals for their destruc-
tion [26,27] at different times after inoculation. Perhaps,
effective immunity could be activated by such manipula-
tion before the manifestation of extensive clinical pathol-
ogy. "Leishmanization" thus may become more effective
or rendered more innocuous. Another possibility is to de-
lete or modify the gene(s) encoding pathoantigenic deter-
minants. Although this is a more desirable approach, it
will require a substantial investment to identify and select
suitable targets. This is the case, since these determinants
appear to be encoded apparently by conserved and thus
functionally important genes. Candidates may include
antigens empirically identified for vaccination against
kala-azar. There may be sufficient incentives to produce
such attenuated mutants in considering the potential ben-
efits that they may be used as vehicle for delivery of anti-
gens as vaccines for other diseases. This may be considered
in view of the "homing" of Leishmania to macrophages
(and possibly dendritic cells). These "vaccines" could be
transgenetically expressed by Leishmania for targeted de-
livery and accumulation in these cells. Antigen processing
and presentation may be rendered more effective to
achieve desirable immune response.
Discussion
Leishmania virulence has been discussed often in the con-
text of infection-related molecules or invasive/evasive de-
terminants, independent of the pathoantigenic
determinants. A hypothetical model is presented to depict
infection, virulence and cure as sequential, but independ-
ent events. The actions of both groups of determinants in
tandem are proposed here to cause leishmaniasis. This hy-
pothetical model is probably applicable to other chronic
infections caused by nontoxigenic pathogens. If so, the
proposed differential targeting strategies could have
broader applications. The actual translation of these ideas
for fighting leishmaniasis and other infectious diseases
into practical use requires additional studies. However
preliminary the schemes may seem, they deserve consid-
eration and discussion for the sake of millions who suffer
from these diseases in the developing world. It is desirable
to develop field deployable products for preventing these
diseases, but this has been hampered by the lack of invest-
ment by the pharmaceutical industry. Hopefully, this ob-
stacle will be rendered easier to overcome under the
coattails of our renewed interests in vaccines in the war
against bioterrorism.
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